GlassScriptPhysician profile
Faris M Tahsin
NPI 1255836672
$6,311.44
in general payments reported to CMS, 2019-2025
21 companies · $2,838 in 2025
The $2,838 reported for 2025 was more than what 92% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $123 · 2021: $879 · 2022: $583 · 2023: $313 · 2024: $1,576 · 2025: $2,838.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,727.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,726.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $1,589.88 | 2021-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $832.72 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $696.88 | 2021-2025 | Caplyta |
| Alkermes, INC. | $563.59 | 2021-2025 | Aristada, Lybalvi |
| E.R. Squibb & Sons, L.L.C. | $449.54 | 2024-2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $434.76 | 2022-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Abbvie INC. | $357.25 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $265.90 | 2024-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Almatica Pharma LLC | $183.42 | 2023-2025 | Loreev Xr |
| Axsome Therapeutics, INC. | $159.77 | 2024-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $141.16 | 2024-2025 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $128.53 | 2024-2025 | Trintellix |
| Bioxcel Therapeutics, INC. | $124.01 | 2023 | Igalmi |
| Sunovion Pharmaceuticals INC. | $122.55 | 2020 | |
| Corium, LLC | $86.72 | 2024 | Azstarys |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $78.36 | 2024-2025 | Rexulti |
| Sage Therapeutics, LLC | $32.98 | 2025 | Zurzuvae |
| Bausch Health US, LLC | $17.37 | 2025 | Aplenzin |
| Supernus Pharmaceuticals, INC. | $16.26 | 2025 | Qelbree |
| Indivior INC. | $15.02 | 2024 | Perseris |
| Owp Pharmaceuticals, INC. | $14.77 | 2025 | Subvenite |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Faris Tahsin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.